Rivaroxaban Revs Up For European Impact
Bayer’s anticoagulant Xarelto® will be eligible in 2026 for generic formulation. Download your free article now to find out more about the opportunities for this bestseller, which earns $12bn in annual sales globally, and over $3.5bn annually in Europe. Discover how to partner with an established supplier to gain the competitive advantage.
26 July 2022